1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62469BD04AC0E8EE8652584C00027DB92
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-thought-leader-service-excellence-establishing-foundation-msls-provide-proactive-compliant-communication-with-kols?OpenDocument
18
19OpenDocument
2018.97.14.89
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Thought Leader Services

Thought Leader Service Excellence: Establishing a Foundation for MSLs to Provide Proactive & Compliant Communication with KOLs

ID: 5592


Features:

5 Info Graphics

9 Data Graphics

80+ Metrics

9 Narratives


Pages/Slides: 17


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Thought Leader Service Excellence: Establishing a Foundation for MSLs to Provide Proactive & Compliant Communication with KOLs”

STUDY OVERVIEW

As the healthcare industry is grappling with a changing marketplace marked by regulatory pressures and access restrictions, it is critical for biopharmaceutical organizations to develop and maintain relationships with key thought leaders. However, many organizations struggle to effectively map and stratify influential thought leaders – and coordinate MSL outreach over time to develop robust relationships with thought leaders.

Best Practices LLC undertook benchmarking research to probe how biopharmaceutical companies are developing integrated systems to provide proactive services to their most influential thought leaders. This study specifically delves into the creation and use of opt-in “standing order” systems – in which thought leaders signal their desire to receive scientific information on an ongoing basis. The study also looks into proactive and reactive MSL interactions.

KEY TOPICS
  • Forging deep thought leader relationships
  • Thought leader segmentation
  • Proactive vs reactive MSL interactions
  • Frequency of MSL interactions
  • Compliance management
  • Managing opt-in “standing order” systems
  • Lessons learned

KEY METRICS
  • Into which segments do you sort the listed types of thought leaders?
  • What percentage of your medical science liaisons’ (MSL) thought leader interactions are proactive vs. reactive?
  • How often do your MSLs conduct the listed proactive activities (meaning information is provided under an existing standing request without formal new written or verbal request)?
  • How long does the opt-in standing request last for a thought leader before it must be updated?
  • Which of the listed systems permit your opt-in (aka standing request) system to work most effectively for the thought leader and for corporate compliance?
  • Does your system provide thought leaders the ability to request they not be contacted by field-based medical liaisons?
  • If a thought leader requests Do Not Solicit / No Communications, is it permanent?
  • Which conditions trigger the removal or resetting of the DNS such that the thought leader can now be contacted by the field team?

SAMPLE KEY FINDINGS
  • TL stratification: Thought leader tiering is a key tool focusing proactive services.
  • Opt-in Standing Order (SO): Nearly 1/3 of companies deploy formal standing orders and up to 79% use informal systems.
  • Duration: SO longevity also supports proactive service with 2/3 of biopharma employing 1 to multi-year durations.

METHODOLOGY

Best Practices, LLC engaged 28 field medical leaders from 23 biopharmaceutical companies across global business units through a benchmarking survey. More than 70% of the participants hold leadership positions at the Director, Vice President and Head level.


Industries Profiled:
Pharmaceutical; Consulting; Medical Device; Biotech; Manufacturing; Health Care; Biopharmaceutical; Communications; Consumer Products; Clinical Research; Laboratories


Companies Profiled:
Adamas Pharmaceuticals; Amplity Health; Baxter International; Biogen; Boehringer Ingelheim; Cardinal Health; Eisai; Fidia; Indivior; Insmed; Insyght; IQVIA; Jazz Pharmaceuticals; LEO Pharma; Merck KGaA; Merck; Mylan; NexGen Healthcare Communications; Novartis; Nutricia; Sandoz; Sanofi; Sunovion

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.